Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Other Non-Current Liabilities (2023 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Other Non-Current Liabilities for 5 consecutive years, with $14.8 million as the latest value for Q1 2026.

  • Quarterly Other Non-Current Liabilities rose 520.51% to $14.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $14.8 million through Jan 2026, up 520.51% year-over-year, with the annual reading at $338000.0 for FY2025, 96.87% down from the prior year.
  • Other Non-Current Liabilities for Q1 2026 was $14.8 million at PharmaCyte Biotech, down from $16.2 million in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $16.2 million in Q4 2025, with the low at $338000.0 in Q2 2025.
  • Average Other Non-Current Liabilities over 4 years is $9.3 million, with a median of $11.1 million recorded in 2024.
  • The sharpest move saw Other Non-Current Liabilities plummeted 96.87% in 2025, then surged 520.51% in 2026.
  • Over 4 years, Other Non-Current Liabilities stood at $11.5 million in 2023, then dropped by 15.86% to $9.7 million in 2024, then soared by 66.86% to $16.2 million in 2025, then decreased by 8.41% to $14.8 million in 2026.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $14.8 million, $16.2 million, and $458000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.